Non-invasive Diagnostics Know Labs is developing a non-invasive glucose monitor using RF dielectric spectroscopy with wearable, mobile, and bench-top form factors, presenting a potential cross-sell opportunity with diabetes care providers, telemedicine platforms, and chronic disease management programs.

Early Public Offering The company recently completed a public offering and trades on NYSE American (KNW), indicating a growth-phase investor base and potential for partnerships or strategic investment discussions with devices manufacturers, diagnostic developers, or healthcare distributors.

Strategic Partnerships Existing collaborations with Edge Impulse for ML acceleration and ongoing algorithm refinement suggest opportunities to bundle know-how in bio-RFID analytics with hardware partners, clinics, or insurers seeking non-invasive monitoring capabilities.

Gen 1 Market Entry With the Gen 1 non-invasive glucose monitor launched in 2023, there is a sales window for pilot programs, clinical studies, and early adopter customers in diabetes/prediabetes management, wearable tech ecosystems, and remote monitoring platforms.

Small Team, NIM Growth Revenue is in the single-digit millions and employee count is lean, signaling a need for scalable partnerships with manufacturers, distributors, or contract research organizations to accelerate production, regulatory clearance, and market access while mitigating internal bandwidth constraints.